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CD40 was initially identifi  ed as a receptor expressed by B cells that is crucial 
for inducing an effective adaptive immune response. CD40 was subsequently 
shown to be expressed by endothelial cells and to promote angiogenesis. New 
data now show that in tumor-prone transgenic mice, CD40-mediated neovas-
cularization is essential for early stage tumorigenicity. This suggests, at least 
in this mouse model, that CD40 has an important role in the angiogenic 
process that is coupled to carcinogenesis, a fi  nding that could lead to novel 
therapeutic opportunities.
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The development of cancer is a com-
plex process (1); both the tumor cells 
and the tumor environment must fulfi  ll 
several requirements to enable a trans-
formed cell to grow into a primary tu-
mor and, eventually, to metastasize to 
distant organs. The fate of a tumor is 
determined both by the immune re-
sponse against the tumor and the vascu-
lature of the host. The immune system 
can attack and destroy transformed cells, 
whereas newly formed vessels in the tu-
mor unwittingly support the survival 
and growth of tumor cells by supplying 
them with oxygen and nutrients. CD40 
is a cell surface protein that is involved in 
both immune responses to tumors and 
in angiogenesis and vascularization. The 
article by Chiodoni et al. (on p. 2441 in 
this issue [2]) shows that the overriding 
role of CD40 in a tumor-prone trans-
genic mouse model of breast cancer is 
to promote neovascularization.
The two faces of CD40
CD40 is expressed by all mature B cells, 
as well as by dendritic cells, macro-
phages, fi  broblasts, epithelial cells, and 
endothelial cells (3, 4). CD40 is crucial 
for the induction of eff  ective adaptive 
immune and infl  ammatory  responses 
(5). The interaction between CD40 
and CD40 ligand (CD40L; also known 
as CD154), which is expressed by acti-
vated T cells, activated B cells, and acti-
vated platelets, promotes both humoral 
and cell-mediated immune responses. 
Indeed, studies using CD40-defi  cient 
mice show that CD40 has an essen-
tial role in T cell–dependent immuno-
globulin class switching, memory B 
cell development, and germinal center 
formation (6, 7). Engagement of CD40 
by CD40L on the surface of human 
endothelial cells induces the activation 
of Ras and phosphatidylinositol 3–ki-
nase (PI3; Fig. 1 A). Activation of this 
signaling pathway leads to the expres-
sion of several angiogenic factors—such 
as vascular endothelial growth factor 
(VEGF) and fi  broblast growth factor 2 
(FGF2)—and promotes angiogenesis in 
xenografts in vivo (5, 8, 9).
These two functions of CD40, in 
promoting both immune responses and 
angiogenesis, have contradictory eff  ects 
on the growth of a tumor. Tumor-spe-
cifi   c immune responses limit tumor 
growth, whereas increased angiogenesis 
supports tumor growth by providing nu-
trients to the tumor cells and providing 
them with a route to distant organs. 
However, although CD40 is expressed by 
blood vessels of renal cell carcinomas (10) 
and Kaposi’s sarcoma (11), so far a re-
quirement for CD40 in neovasculariza-
tion of tumors has not been established 
experimentally. Determining whether 
CD40 has more of an eff  ect on antitumor 
immune responses or tumor vasculariza-
tion may have important implications for 
the design and implementation of thera-
peutics that target this molecule.
Which face of CD40 leads the way?
To test the role of CD40 in the 
development of mammary carcinomas, 
Chiodoni et al. crossed transgenic mice 
expressing the Her2/neu oncogene under 
the control of the mouse mammary tu-
mor virus promoter with CD40-defi  cient 
mice, and compared tumor onset and 
progression in these mice with that 
in CD40-suffi   cient  Her2/neu-transgenic 
mice (2). Remarkably, the analysis of tu-
mors in the CD40-defi  cient  transgenic 
mice showed increased latency, reduced 
numbers of tumors, and decreased total 
tumor size in comparison to the CD40-
suffi     cient mice. These fi  ndings  were 
  surprising. Because CD40 is crucial in 
mounting an immune response, one 
would predict that mice lacking this pro-
tein would be more prone to tumors than 
their CD40-suffi   cient counterparts.
The reduced tumorigenicity was not 
a result of a functional defect in CD40-
defi  cient bone marrow–derived cells in 
the tumor microenvironment. Rather, a 
lack of CD40 on endothelial cells im-
paired tumor angiogenesis, leading to a 
block in tumor growth. Indeed, in Matri-
gel implantation assays, the authors found 
that the interaction between CD40L (or 
an antibody specifi  c for CD40) and CD40 
on mouse endothelial cells triggered ves-
sel formation in vivo. When the forma-
tion of tumor-associated blood vessels was 
analyzed in the mice, striking defects in 
the size, number, and organization of 
these vessels were observed in the absence 
of CD40 (2).
These data suggest, at least in this 
model, that CD40 is required to establish 
a blood supply for the tumor. The au-
thors next investigated CD40L ex  pression 
in the tumor tissue. It is well known 
that CD40L is expressed by acti  vated 
CD4+ T cells (12, 13). More recently, 
CD40L has also been detected on hu-
man platelets, which release the soluble 
form of CD40L upon activation (14, 15). 
Because CD4+ T cells are absent 
from the tumors in Her2/neu-transgenic 
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mice, the authors focused on platelets. 
Treatment of CD40-suffi   cient  Her2/
neu-transgenic mice with Clopidogrel, 
a drug that blocks platelet aggregation 
and the release of soluble CD40L 
(16, 17), decreased both the tumor size 
and number. These data led the authors 
to suggest that the eff  ect of Clopidogrel 
on tumor growth is probably caused by 
the inhibition of platelet activation and, 
therefore, the inhibition of CD40L 
release (Fig. 1 B).
The tumor environment 
and tumorigenesis
The tumor microenvironment has a ma-
jor impact on tumor growth, invasion 
into the bloodstream, and metastasis. 
Diff  erent cell populations present in the 
microenvironment aff  ect these processes 
in distinct ways. For example, recent 
studies (18, 19) have shown that myeloid 
cells within tumors are not passive struc-
tural elements. Rather, these cells can 
take up tumor antigens and, upon matu-
ration and activation, migrate to draining 
lymph nodes, where they can elicit a tu-
mor-specifi  c immune response. In con-
trast, activation of bone marrow–derived 
cells in the tumor can induce an infl  am-
matory reaction, which either promotes 
or inhibits tumorigenesis. Furthermore, 
bone marrow–derived progenitors in the 
tumor can generate endothelial cells and 
hematopoietic cells that support tumor 
growth and metastasis to diff  erent organs 
through angiogenesis (20).
Soluble factors in the tumor micro-
environment also infl  uence  tumor 
growth and metastasis. Neovasculariza-
tion, for example, is regulated by factors 
that either promote or inhibit angio-
genesis. VEGF, FGF1, and FGF2 are 
known to trigger angiogenesis by bind-
ing to tyrosine kinase receptors on en-
dothelial cells, inducing proliferation 
of the vasculature (21, 22). A proto-
typical angiogenesis inhibitor is throm-
bospondin-1, which binds CD36, a 
transmembrane receptor expressed by 
endothelial cells that is coupled to in-
tracellular SRC-like tyrosine kinases 
(23). This signaling pathway leads to the 
expression of Fas ligand (also known as 
CD95L) by endothelial cells and their 
subsequent apoptosis (23).
In general, the relative amounts of the 
diff  erent activators and inhibitors dictate 
whether an endothelial cell will be in a 
quiescent or proangiogenic state. During 
tumor development, neovascularization is 
initiated by an “angiogenic switch,” which 
alters the appropriate balance between the 
activating and inhibitory signals received 
by an endothelial cell and causes the en-
dothelial cells to proliferate (24).
Until recently, the predominant view 
on the vascularization of a tumor was 
“tumor centric,” whereby the tumor in-
duces angiogenesis by either secretion of 
proangiogenic factors and/or by tran-
scriptional down-regulation of the ex-
pression of angiogenic inhibitors. Now, 
the observations of Chiodoni et al. (2), 
along with other recent publications (25, 
26), show that the induction of proan-
giogenic factors by the tumor alone is 
not suffi   cient. Rather, the tumor and its 
environment have a dynamic relation-
ship that results in neovascularization and 
the promotion of tumor growth.
The importance of timing
The report by Chiodoni et al. (2) also 
demonstrates that the same protein can 
have diff  erent functions in distinct physi-
ological compartments in the tumor en-
vironment and, thus, can either promote 
or inhibit tumorigenesis. In the breast 
cancer model used by Chiodoni et al., the 
proangiogenic role of CD40 is dominant 
over its role in generating an antitumor 
immune response, thus promoting tumor 
progression (2). The opposite was true, 
however, when the authors transplanted 
fast-growing tumor cell lines derived 
from  Her2/neu-transgenic mice into 
CD40-defi   cient or CD40-suffi   cient 
mice. Under these conditions, more ag-
gressive tumors developed in CD40-
defi  cient mice than in CD40-suffi   cient 
mice (2). In this transplant model of 
breast cancer, the transplanted tumor 
cells have already been selected for tu-
morigenic and malignant potential, and 
the immunological role of CD40 pre-
vailed over the proangiogenic eff  ect. 
Hence, it is not possible to focus only 
on the proangiogenic aspect of CD40 
function and to neglect its role in im-
munosurveillance. This study seems to 
indicate that the   involvement of CD40 
in immune responses is more important 
during later stages of tumorigenesis.
The absence of CD40 might there-
fore have diff  erent outcomes on tumor 
growth depending on the stage of tu-
mor development. In this breast cancer 
model, a lack of CD40 before tumors 
arise inhibited tumor growth, whereas a 
Figure 1.  CD40 signaling regulates angiogenesis. (A) CD40-induced signaling pathway in 
  endothelial cells. Interaction of CD40L with CD40 on the surface of endothelial cells results in 
  activation of the Ras signaling pathway. Ras associates with PI3 to induce the expression of VEGF, 
which in turn stimulates angiogenesis. Platelets are likely to be a major, but not unique, source of 
CD40L (see The two faces of CD40). (B) Platelets induce neoangiogenesis. Activation of platelets 
causes them to release a soluble form of CD40L, which can bind CD40 on the surface of endothelial 
cells. Stimulation of CD40 on endothelial cells activates them and, in a tumor, leads to neovascular-
ization of the tumor. The antiplatelet drug Clopidogrel blocks CD40L secretion by platelets and 
thereby inhibits neovascularization.COMMENTARY
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lack of CD40 at later stages of tumor 
development enhanced tumorigenicity 
and caused a more severe outcome. 
However, this conclusion is somewhat 
surprising, as it is generally assumed that 
advanced tumors are more dependent 
on neovascularization than early stage 
tumors. It is therefore essential to clearly 
defi   ne the tumor stage at which the 
switch from CD40-dependent vascu-
larization to CD40-independent vascu-
larization takes place and to understand 
what causes CD40 independence of 
late-stage tumors. 
Based on the observations of 
Chiodoni et al. (2), it is conceivable that 
the activation of endothelial cells by 
CD40 is an early event in tumorigenesis, 
whereas multiple angiogenic stimuli be-
come available later in tumor progression 
and render CD40 expression by endo-
thelial cells dispensable. It is now neces-
sary to identify these other angiogenic 
factors and to understand how they stim-
ulate vascularization independently of 
CD40. 
Experiments with antiangiogenesis 
factors in a mouse model of pancreatic is-
let carcinogenesis have shown that the ef-
fi  cacy of angiogenesis inhibitors depends 
on the stage of tumor development: some 
inhibitors of angiogenesis are successful 
for the treatment of early stage disease but 
do not cause regression of end-stage tu-
mors, whereas others are eff  ective at re-
ducing the mass of end-stage tumors but 
have no eff  ect on preventing progression 
during early stage disease (27). Therefore, 
the actual mechanism of tumor neovascu-
larization seems to depend on the stage of 
tumor development, and specifi  c  pro- 
and antiangiogenic factors seem to be rel-
evant at diff  erent stages of the disease. It is 
interesting to speculate that the respon-
siveness of tumor-associated endothelial 
cells to stimulation through CD40 and/or 
their level of expression of CD40 have a 
role in mediating the outcome of diff  er-
ent antiangiogenesis therapies.
The complexities of targeted tumor 
therapy against cancer
Another important observation of the 
paper by Chiodoni et al. (2) is the pos-
sible identifi  cation of the cells that are 
responsible for CD40-triggered angio-
genesis. Because treatment of CD40-
suffi   cient  Her2/neu-transgenic mice 
with the antiplatelet drug Clopidogrel 
reduced tumor growth, it seems proba-
ble that platelets are responsible for 
CD40-triggered angiogenesis in this 
model. However, cell types other than 
platelets also express CD40L, and these 
cells could activate CD40 if located in a 
tumor. The ability of such cells to re-
side in the tumor or be recruited to a 
tumor could diff   er depending on the 
type of tumor or the stage of tumor de-
velopment. Indeed, although T cells 
were absent from the tumors analyzed 
by Chiodoni et al., T cells are often 
found in leukocyte infi  ltrates in human 
breast carcinoma (28). Therefore, in 
diff  erent breast cancer models T cells 
could have a more prominent role as 
CD40L-expressing cells in the tumor. 
Furthermore, as endothelial cells ex-
press CD40L (29), one could envision 
an “autocrine” CD40–CD40L stimu-
lating circuit within the endothelium.
Tumor angiogenesis off  ers  an 
attractive target for the treatment of 
individuals with cancer, and several an-
tiangiogenic drugs are already in use, 
albeit with variable therapeutic success 
(30). A combinatorial approach to treat-
ment that targets both cancer cells and 
the surrounding stroma might prove 
more promising than using single anti-
angiogenic agents.
Chiodoni et al. suggest a novel and 
intriguing approach to the treatment of 
cancer: the use of anticoagulants to pre-
vent the interaction between platelets 
and endothelial cell progenitors in the 
tumor, thereby blocking the CD40–
CD40L interaction that causes platelets 
to promote tumor angiogenesis. So far, 
therapies targeting CD40 have been 
  designed to trigger CD40 signaling and 
thus boost the immune response against 
the tumor (31). But this approach might 
be a double-edged sword, because pro-
moting CD40 expression might also 
promote angiogenesis. 
Importantly, as in the previous para-
graph, the eff  ect of CD40 loss on tumori-
genesis diff  ers depending on the stage of 
tumor development, which therefore has 
implications for therapy. Although down-
regulation of CD40 expression might be 
desirable during early tumor develop-
ment, it could have catastrophic conse-
quences at later stages, when a tumor is 
more aggressive, by inhibiting the tumor-
specifi  c immune response. It is also im-
portant to point out that this study focuses 
exclusively on mammary tumors. Al-
though the authors show that CD40 is 
required for neovascularization and 
growth of carcinomas in a model of breast 
cancer, other tumor types, especially more 
aggressive and faster growing tumors, 
might not be dependent on CD40. For 
this reason, the use of a CD40-based ther-
apy for cancer is premature at this stage. 
Nevertheless, this study clearly highlights 
the fact that a targeted therapy has to be 
tailored not only to the genetic makeup 
of the tumor but also to the particular 
stage of tumor progression and the intri-
cate relationship between the tumor and 
its stromal environment.
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